10 selected publications:

• Development of a NanoBRET assay to validate inhibitors of Sirt2-mediated lysine deacetylation and defatty-acylation that block prostate cancer cell migration.
  Vogelmann A, Schiedel M, Wössner N, Merz A, Herp D, Hammelmann S, Colcerasa A, Komaniecki G, Hong JY, Sum M, Metzger E, Neuwirt E, Zhang L, Einsle O, Groß O, Schüle R, Lin H, Sippl W and Jung M. (2022)
  RSC Chem. Biol. 3 468-485.
• Nitroreductase-mediated release of inhibitors of Lysine-Specific Demethylase 1 (LSD1) from prodrugs in transfected acute myeloid leukaemia cells.
  Herrlinger E-M^#, Hau M, Redhaber DM, Greve G, Willmann D, Steimle S, Müller M, Lübbert M, Miething CC, Schüle R, and Jung M. (2020)
  ChemBioChem 21: 2329-2347.
• Structure-reactivity relationships on substrates and inhibitors of the lysine deacylase Sirtuin 2 from Schistosoma mansoni (SmSirt2). Monaldi D, Rotili D, Lancelot J, Marek M, Lucidi A, Tomaselli D, Ramos-Morales E, Romier C, Pierce RJ, Mai A, and Jung M. (2019).
  J. Med. Chem. 62: 8733-8759.
• KMT9 mono-methylates histone H4 Lysine 12 and controls proliferation of prostate cancer cells. Metzger E, Wang S, Urban S, Willmann D, Schmidt A, Offermann A, Allen A, Sum M, Obier N, Cottard F, Ulferts S, Preca B-T, Herrmann B, Maurer J, Greschik H, Hornung V, Einsle O, Perner S, Imhof A, Jung M, and Schüle R. (2019).
  Nat. Struct. Mol. Biol. 26: 361–371.
• The clinically used iron chelator deferasirox is an inhibitor of epigenetic JumonjiC domain-containing histone demethylases.
  Roatsch M, Hoffmann I, Abboud MI, Hancock RL, Tarhonskaya H, Hsu K-F, Wilkins SE, Yeh T-L, Lippl K, Serrer K, Moneke I, Ahrens TD, Robaa D, Wenzler S, Barthes NPF, Franz H, Sippl W, Lassmann S, Diederichs S, Schleicher E, Schofield CJ, Kawamura A, Schüle R, and Jung M. (2019).
  ACS Chem. Biol. 14: 1737-1750.
• Structure-activity studies on N-substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation.
  Schulz-Fincke J, Hau M, Barth J, Robaa D, Willmann D, Kürner A, Haas J, Greve G, Haydn T, Fulda S, Lübbert M, Lüdeke S, Berg T, Sippl W, Schüle R and Jung M. (2018).
  Eur. J. Med. Chem. 144: 52-67.
• Chemically induced degradation of sirtuin 2 (Sirt2) by a proteolysis targeting chimera (PROTAC) based on sirtuin rearranging ligands (SirReals).
  Schiedel M, Herp D, Hammelmann S, Swyter S, Lehotzky A, Robaa D, Oláh J, Ovádi J, Sippl W, and Jung M; J. (2018).
  Med. Chem. 61: 482-491.
• Structure-based Development of a Sirtuin 2 Affinity Probe.
  Schiedel M, Rumpf T, Karaman B, Lehotzky A, Gerhardt S, Ovádi J, Sippl W, Einsle O, and Jung M. (2016).
  Angew. Chem. Int. Ed. 55: 2252-2256.
• Assembly of methylated LSD1 and CHD1 drives AR dependent transcription and translocation. Metzger E, Willmann D, McMillan J, Forne I, Metzger P, Gerhardt S, Petroll K, von Maessenhausen A, Urban S, Schott A-K, Espejo A, Eberlin A, Wohlwend D, Schüle KM, Schleicher M, Perner S, Bedford MT, Jung M, Dengjel H, Flaig R, Imhof A, Einsle O, Schüle R. (2016).
  Nat. Struct. Mol. Biol. 23: 132-139.
• Selective Sirt2-inhibition by ligand-induced rearrangement of the active site.
  Rumpf T, Schiedel M, Karaman B, Roessler C, North BJ, Lehotzky A, Olah J, Ladwein KI, Schmidtkunz K, Gajer M, Pannek M, Steegborn C, Sinclair DA, Gerhardt S, Ovadi J, Schutkowski M, Sippl W, Einsle O and Jung M. (2015)
  Nat. Commun. 6: 6263.